Expert panel recommends targeted prostate cancer screening only for men with specific gene mutations.
Articles on PSA test
Displaying all articles
Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.
Men who had radiotherapy to treat their prostate cancer were three times more likely to develop bladder cancer compared with untreated men.
Prostate cancer is one of the most common cancers in men. Although watchful waiting is appropriate for low-risk cases, many are diagnosed at an advanced stage because of racial health disparities.
New research estimates 24% of cancers in men that were detected in 2012 were overdiagnosed, meaning they never would have caused harm if left untreated.
Men with faults in their BRCA2 gene are at higher risk of aggressive prostate cancer.
Since the 1980s, PSA tests have been used for the diagnosis and follow-up of prostate cancer. However, its use as a screening test for prostate cancer remains controversial.
A family physician and public health researcher explains why he isn’t getting a prostate cancer test in Movember or at any time in the near future.
Top contributors
-
Senior Lecturer in Chemical Pathology, University of Westminster
-
Professor of Family Medicine, University of Calgary
-
Professor of Surgery, Eastern Health Clinical School, Monash University
-
Professor of Clinical Epidemiology, Sydney School of Public Health, University of Sydney
-
MB BS Phase 1 Lead & Senior Lecturer in Medicine and Molecular Genetics, University of York
-
Professor of Medicine, Bond University
-
Senior Associate Vice President Community Health, Education and Training, Old Dominion University; Associate Professor of Pharmacy, University of Florida
-
Senior Lecturer, School of Medicine, Griffith University
-
Professor of Public Health, University of Sydney
-
Associate Professor, Biostatistician, Institute for Evidence-Based Healthcare, Bond University
-
Fellow of the European Board of Urology, University of Tübingen
-
Professor of Cellular and Molecular Biology, University of Westminster
-
Lecturer, Cancer Institute, UCL